UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________________________________ FORM 10-Q ________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39264 _______________________________________ ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ________________________________________ (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39264 KEROS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) _____ ...

*** KEROS KER-050 Update June 2022 Disclaimer Statements contained in this presentation regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as "anticipates," "believes," "expects," "intends," "plans," "potential," "projects," "would" and "future" or similar expressions are intended to identify forward-looking statements. Examples of these forward-looking statements include statemen ...

*** KEROS Corporate Update May 2022 Disclaimer Statements contained in this presentation regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as "anticipates," "believes," "expects," "intends," "plans," "potential," "projects," "would" and "future" or similar expressions are intended to identify forward-looking statements. Examples of these forward-looking statements include stateme ...

| --- | --- | |-----------|-----------------------------------------------------------------------| | | | | | | | | | | Selective | Inhibition of ALK‐2 Signaling Ameliorates Disease in a | | Novel | Model of Iron Refractory Iron Deficiency Anemia (IRIDA) | | | Thomas Backus Natalia Medeiros, Evan Lema, ffolliott | | | , Fisher, Jasbir Seehra, Jennifer Lachey | | | Keros Therapeutics, Lexington MA, USA | | | June 2020 | | | in Focus | | | | | | | Disclosure All listed authors are employees of and shareholder ...